In addition to GLP-1 agonists, such as Ozempic, Wegovy, Trulicity, Mounjaro, and Zepbound, other medications and substances can cause gastroparesis
Dapagliflozin is a weak substrate of the P-glycoprotein (P-gp) active transporter, and dapagliflozin 3-O-glucuronide is a substrate for the OAT3 active transporter
Understanding the evidence, recognising who may be at higher risk, and maintaining appropriate eye screening can help patients benefit from these medications whilst protecting their sight
Understanding these can help patients make informed decisions when exploring their options, particularly in the private sector where pricing is less standardised
A small-molecule oral triple agonist, one of four GPCR programs under the May 2025 Septerna-Novo Nordisk collaboration (up to $2.2B total deal value, $200M+ upfront)